Details

Autor(en) / Beteiligte

• Hüttenrauch, Melanie
• Ogorek, Isabella
• Klafki, Hans
• Otto, Markus
• Stadelmann, Christine
• Weggen, Sascha
• Wiltfang, Jens
• Wirths, Oliver

Titel

Glycoprotein NMB: a novel Alzheimer's disease associated marker expressed in a subset of activated microglia

Ist Teil von

• Acta neuropathologica communications, 2018-10, Vol.6 (1), p.108-108, Article 108

Ort / Verlag

England: BioMed Central Ltd

Erscheinungsjahr

2018

Quelle

2022 ECC(Springer)

Beschreibungen/Notizen

• Alzheimer's disease (AD) is an irreversible, devastating neurodegenerative brain disorder characterized by the loss of neurons and subsequent cognitive decline. Despite considerable progress in the understanding of the pathophysiology of AD, the precise molecular mechanisms that cause the disease remain elusive. By now, there is ample evidence that activated microglia have a critical role in the initiation and progression of AD. The present study describes the identification of Glycoprotein nonmetastatic melanoma protein B (GPNMB) as a novel AD-related factor in both transgenic mice and sporadic AD patients by expression profiling, immunohistochemistry and ELISA measurements. We show that GPNMB levels increase in an age-dependent manner in transgenic AD models showing profound cerebral neuron loss and demonstrate that GPNMB co-localizes with a distinct population of IBA1-positive microglia cells that cluster around amyloid plaques. Our data further indicate that GPNMB is part of a microglia activation state that is only present under neurodegenerative conditions and that is characterized by the up-regulation of a subset of genes including TREM2, APOE and CST7. In agreement, we provide in vitro evidence that soluble Aβ has a direct effect on GPNMB expression in an immortalized microglia cell line. Importantly, we show for the first time that GPNMB is elevated in brain samples and cerebrospinal fluid (CSF) of sporadic AD patients when compared to non-demented controls.The current findings indicate that GPNMB represents a novel disease-associated marker that appears to play a role in the neuroinflammatory response of AD.